Cresco Labs Inc. (OTCMKTS:CRLBF) Receives Average Recommendation of “Moderate Buy” from Brokerages

Cresco Labs Inc. (OTCMKTS:CRLBF) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $2.50.

Several research firms have commented on CRLBF. Cormark lowered shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a research note on Monday, November 11th. Atb Cap Markets lowered Cresco Labs from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, Roth Capital raised Cresco Labs to a “strong-buy” rating in a report on Sunday, November 10th.

Cresco Labs Price Performance

Shares of CRLBF opened at $0.98 on Friday. The stock has a market cap of $475.94 million, a P/E ratio of -4.88 and a beta of 1.73. The business’s fifty day moving average is $1.37 and its 200 day moving average is $1.57. The company has a quick ratio of 1.39, a current ratio of 1.97 and a debt-to-equity ratio of 1.80. Cresco Labs has a 12-month low of $0.96 and a 12-month high of $2.65.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.